The efficacy of recognan in the early stage of ischemic stroke

Mashin V.V.; Belova L.A.; Dudikov E.M.; Bergelson T.M.; Lankov V.A.; Zakuraeva K.A.

doi:https://doi.org/10.17116/jnevro201711710144-48

Mashin V.V.

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Dudikov E.M.

Ulyanovsk State University, Ulyanovsk, Russia

Bergelson T.M.

The Ulyanovsk State University, Ulyanovsk, Russia

Lankov V.A.

Ulyanovsk State University, Ulyanovsk, Russia

Zakuraeva K.A.

Ulyanovsk State University, Ulyanovsk, Russia

The efficacy of recognan in the early stage of ischemic stroke

Authors:

Mashin V.V., Belova L.A., Dudikov E.M., Bergelson T.M., Lankov V.A., Zakuraeva K.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10): 44‑48

DOI: 10.17116/jnevro201711710144-48

Read: 4358 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mashin VV, Belova LA, Dudikov EM, Bergelson TM, Lankov VA, Zakuraeva KA. The efficacy of recognan in the early stage of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):44‑48. (In Russ.)
https://doi.org/10.17116/jnevro201711710144-48

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Features of care of patients with cardiovascular diseases and cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104

Cerebrovascular disease in clinical practice. Resolution of the Expert Council of the Russian Scientific Medical Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111

Efficacy of Recognan in the therapy of neurological disorders after traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):41-45

Chronic traumatic encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):16-24

Cardiogenic dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49

Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):85-95

Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):133-139

Effectiveness of “brain—computer” interfaces with biofeedback in the rehabilitation of cognitive impairment after a stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):54-60

Cognitive rehabilitation technology using a combination of postural training and simultaneous cognitive task in prevention of cognitive impairment after coronary artery bypass grafting. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):418-427

The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478

Abstract:

Objective. To assess the efficacy and safety of recognan in patients with acute ischemic stroke (IS). Material and methods. Seventy-nine patients, aged from 30 to 80 years, were examined in the early stage of IS. All patients received recognan (citicoline) in dose of 1000 mg/daily during 15 days. The recovery of cognitive functions (MMSE), level of consciousness (Glasgow Coma Scale), severity of focal neurological deficit (NIHSS) and functional recovery (Rankin scale, Barthel index, Rivermead Mobility Index) were assessed. Results and conclusion. A decrease of cognitive impairment, improvement of memory, regression of neurological symptoms and increase in the motor activity were observed. Recognan used in dose of 1000 mg/daily during 15 days in the complex treatment of patients with IS promotes the recovery of cognitive function, reduces neurological symptoms and improves the recovery of motor activity.

Keywords:

recognan

citicoline

cognitive impairment

acute ischemic stroke

motor activity

Authors:

Mashin V.V.

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Dudikov E.M.

Ulyanovsk State University, Ulyanovsk, Russia

Bergelson T.M.

The Ulyanovsk State University, Ulyanovsk, Russia

Lankov V.A.

Ulyanovsk State University, Ulyanovsk, Russia

Zakuraeva K.A.

Ulyanovsk State University, Ulyanovsk, Russia

Close metadata

References:

Suslina ZA, Fonyakin AV, Geraskina LA, Mashin VV i dr. Prakticheskaya kardionevrologiya. Pod red. Suslinoi Z.A., Fonyakina A.V. M: IMA-PRESS; 2010. (In Russ.)
Belova LA, Mashin VV, Saprigina LV, Kravchenko MA, Gnedovskaya EV, Oshepkova EV, Varakin YuYa, Suslina ZA. Struktura zerebrovaskulyarnoi patologii v otkritoy populyazii pabotosposobnogo naseleniya g. Ulyanovska. Annali klinicheskoi i experimentalnoi nevrologii. 2014;4(8):4-8. (In Russ.)
Reis C, Akyol O, Ho WM, Araujo C, Huang L, Applegate RII, Zhang JH. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. Biomed Res Int. 2017; 2017:4863079.
Lee BK, Jung YS. Sustained Intracellular Acidosis Triggers the Na+/H+ Exchager-1 Activation in Glutamate Excitotoxicity. Biomol Ther (Seoul). 2017 Jun 14. https://doi.org/10.4062/biomolther.2017.018
Lloyd-Evans E. Acidic Ca²⁺ stores in neurodegeneration. Messenger (Los Angel). 2016;5(1-2):37-55. https://doi.org/10.1166/msr.2016.1054.
Cisneros-Mejorado A, Gottlieb M, Ruiz A, Chara JC. Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage. J Cereb Blood Flow Metab. 2017:271678X17713587. https://doi.org/10.1177/0271678X17713587
Michael S. Ritsner. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Springer. 2010;663. https://doi.org/10.1007/978-90-481-8553-5
Secades JJ Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(03):1-73.
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsyannikova AN. Effectivnost Korteksina v ostrom i vosstanovitelnom periodakh polusharnogo insulta. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116:10:38-42. (In Russ.)
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsyannikova AN. Dinamika kognitivnikh narusheniy u bolynikh s polusharnym ishemicheskim insultom v ostrom i rannem vosstanovitelnom periodakh na fone niskodoznoi neiroprotekzii preparatom Korteksin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (Insult). 2016;116:8(2):40-43. (In Russ.)
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
Karsy M1, Brock A1, Guan J1, Taussky P1 Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus. 2017;42(4):3. https://doi.org/10.3171/2017.1.FOCUS16522
Yuliani S, Widyarini S, Mustofa, Partadiredja G Turmeric extract inhibits apoptosis of hippocampal neurons of trimethyltin-exposed rats. Bratisl Lek Listy. 2017;118(3):142-148. https://doi.org/10.4149/BLL_2017_028
Secades JJ1, Alvarez-Sabín J2, Castillo J3 Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Rand omized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010